Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
Holding AGEN?
Track your performance easily
AGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.50 - $19.69
Previous Close$2.57
Volume504.59K
Average Volume (3M)438.68K
Market Cap
$60.29M
Enterprise Value$107.03M
Total Cash (Recent Filing)$44.78M
Total Debt (Recent Filing)$70.99M
Price to Earnings (P/E)―
Beta3.45
Next Earnings
Mar 13, 2025EPS Estimate
-$2.6Last Dividend Ex-Date
Apr 26, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-11.00
Shares Outstanding23,458,929
10 Day Avg. Volume845,454
30 Day Avg. Volume438,682
Standard Deviation0.21
R-Squared0.11
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.21
Price to Sales (P/S)0.38
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit-1.32
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$9.00Price Target Upside237.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Agenus News
PremiumCompany Announcements
Agenus Inc. Reports Progress in Immunotherapy Development
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe EMA has agreed on dose selection and trial design for the Phase 3 trial, which is a significant step forward for the company's clinical progress.
Competitive AdvantagePeer abstract highlights the low efficacy of control treatments, suggesting a competitive advantage for Agenus's treatment.
Safety And EfficacyUpdated efficacy data showed promising results in patients with different metastatic sites, indicating durable efficacy.
Bears Say
Cash FlowThe company's cash runway seems to not extend beyond two quarters, which is a key driver of a significant sell-off.
Regulatory ApprovalThe EMA advised against conditional approval, contrary to what was expected by the company.
Stock PriceExpected dilution from a cash influx is the primary driver of the price target lowering from $18 to $11.
---
Ownership Overview
11.22% Insiders
17.36% Mutual Funds
4.79% Other Institutional Investors
57.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $2.50 and its highest was $19.69 in the past 12 months.
What is Agenus’s market cap?
Currently, no data Available
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Mar 13, 2025 which is in 112 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Nov 12, 2024. The company reported -$3.08 earnings per share for the quarter, missing the consensus estimate of -$2.314 by -$0.766.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on Agenus dividends here
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -$2.6.
How many shares outstanding does Agenus have?
Agenus has 23,458,930 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$3.08 in its last earnings report, missing expectations of -$2.314. Following the earnings report the stock price went down -20.513%.
Which hedge fund is a major shareholder of Agenus?
Among the largest hedge funds holding Agenus’s share is Woodline Partners LP. It holds Agenus’s shares valued at 604K.
---
Agenus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (237.08% Upside)
$9.00 (237.08% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 85%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.91%
Trailing 12-Months
Company Description
Agenus
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
---
AGEN Earnings Call
Q3 2024
0:00 / 0:00
---
AGEN Stock 12 Month Forecast
Average Price Target
$9.00
▲(237.08% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Fate Therapeutics
―
MacroGenics
―
Karyopharm Therapeutics
―
Best Analysts Covering AGEN
1 Year
1 Year Success Rate
1/32 ratings generated profit
1 Year Average Return
-52.87%
reiterated a buy rating 3 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 3.13% of your transactions generating a profit, with an average return of -52.87% per trade.
---